SIP
LAB icon

Stoneridge Investment Partners’s Standard BioTools LAB Stock Holding History

Stoneridge Investment Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25,293
Closed -$144K – 286
2017
Q1 		$144K Buy
25,293
+1,013
+4% +$6.42K 0.02% 295
2016
Q4 		$177K Hold
24,280
– – 0.02% 272
2016
Q3 		$194K Sell
24,280
-116
-0.5% -$1.06K 0.03% 247
2016
Q2 		$220K Buy
+24,396
New +$229K 0.03% 248

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stoneridge Investment Partners's LAB Position: Q2 2017 in Review

Stoneridge Investment Partners sold out of Standard BioTools (LAB) in Q2 2017, closing a stake of 25,293 shares — an estimated $144K sold.

Stoneridge Investment Partners first reported a position in LAB in Q2 2016 and held it in 4 quarters. The position peaked at $220K in Q2 2016. 80 funds tracked by Wall St. Rank hold LAB as of Q2 2017.

  • Stoneridge Investment Partners reported no remaining Standard BioTools position as of Q2 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 25,293 Standard BioTools shares in Q2 2017, an estimated $144K.
  • Stoneridge Investment Partners first reported a position in Standard BioTools in Q2 2016 and held it in 4 quarters.
  • Stoneridge Investment Partners's Standard BioTools position peaked at $220K in Q2 2016.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2017.

Based on Stoneridge Investment Partners's 13F filing for Q2 2017, filed 1 Aug 2017.